Jha, R.K.; Tiwari, S.; Mishra, B.
(Springer New York LLC, 2011-06)
Raloxifene hydrochloride (R-HCl), a BCS class II drug, remains a mainstay in the prevention and pharmacologic therapy of osteoporosis. Its absolute bioavailability, however, is 2% due to poor solubility and extensive first ...